课题基金 / 基金详情

Administrative Supplement to Hepatobiology and Toxicology COBRE

Administrative Supplement to Hepatobiology and Toxicology COBRE
肝生物学和毒理学 COBRE 行政增刊
批准号:
10399887
负责人:
CRAIG J. MCCLAIN
金额:
$25.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-01 至 2022-03-31

项目摘要

项目成果

CRAIG J. MCCLAIN的其他基金

相似基金

相关文献

中文摘要
翻译
路易斯维尔大学(UofL)肝脏生物学和毒理学(H&T)科布雷是一个独特的主题 中心专注于肝脏研究。UofL H&T Cobre专注于机制和治疗 应对多种形式的肝脏疾病/损伤的策略,包括:非酒精性脂肪性肝病/非酒精性脂肪性肝病 脂肪性肝炎--美国/全球最常见的肝病,与代谢密切相关 酒精性肝病-饮酒者的常见问题;环境毒物 诱发性肝损伤--一个日益被认识到的问题,路易斯维尔在这一领域一直处于领先地位; 乙型和丙型肝炎--全球范围内导致肝硬变和肝细胞癌的重要原因;个性化 药物--药物疗效的一个越来越重要的因素,大多数药物在肝脏中代谢; 和药物引起的肝损伤-最常见的原因是药物从市场上下架, 导致肝功能衰竭的重要原因。Cobre汇集了经验丰富的高级导师/调查人员和 有前途的初级研究人员将在独特的肝生物学和 毒物学。我们解决了我们在理解肝脏疾病的发展/进展方面的关键障碍 我们还确定了可能改变临床实践的预防/治疗目标。 肝脏生物学和毒理学中心的具体目标是: 1.扩大和加强以主题为重点的肝生物学和毒理学项目,帮助建立 并维持UofL的整体研究基础设施。 2.扩大和加强研究教育、指导和职业方面的多学科计划 肝生物学和毒理学的发展,并系统跟踪和评估进展。 3.提供必要的研究资源和转化科学/基础技术,以支持 在肝脏生物学和毒理学方面进行最先进的研究,并确保该计划的可持续性。 4.发现预防和/或治疗肝脏的新机制/分子靶点和有效手段 疾病/毒物暴露,并向公众公布我们的研究结果。 总之,第一阶段加强了UofL的生物医学研究基础设施,通过建立 肝脏生物学和毒理学的多学科专题中心,以提高研究人员的能力 争取独立的资金。在第一阶段,我们达到或超过了我们的指标,包括1)我们的 研究人员向独立研究基金过渡;2)91名导师和162篇出版物;3)新的 翻新的实验室空间;4)大量演示;5)建立新的合作关系;以及6)>75美元 由H&T成员提供的新赠款资金总额为100万美元。这项第二阶段计划建立在我们第一阶段成功的基础上, 扩大和加强了该计划的范围,并提供了可持续发展的路线图。
英文摘要
The University of Louisville (UofL) Hepatobiology and Toxicology (H&T) COBRE is a unique thematic center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic strategies for multiple forms of liver disease/injury, including: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis—the most common liver disease in the US/worldwide, and is highly linked to the metabolic syndrome; Alcoholic Liver Disease—a common problem among those who drink; Environmental Toxicant Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area; Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver; and Drug-Induced Liver Injury—the most common reason drugs are removed from the market and an important cause of liver failure. This COBRE brings together experienced senior mentors/investigators and promising junior investigators to perform cross-cutting research on the unique topics of Hepatobiology and Toxicology. We address critical barriers in our understanding of the development/ progression of liver disease and we define targets for prevention/treatment that could transform clinical practice. Specific Aims of the Hepatobiology and Toxicology COBRE are to: 1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology that helps build and sustain the overall research infrastructure at UofL. 2. Expand and strengthen the multidisciplinary program in research education, mentoring and career development in Hepatobiology and Toxicology, and systematically track and evaluate the progress. 3. Provide the necessary research resources and translational science/basic technologies to support state-of- the-art research in Hepatobiology and Toxicology and to ensure sustainability of the program. 4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver diseases/toxicant exposures and communicate our findings to the public. In summary, Phase I strengthened UofL’s biomedical research infrastructure through the establishment of a thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to compete for independent funding. In Phase I, we met or exceeded our metrics, including 1) four of our investigators transitioning to independent research funding; 2) 91 mentee and 162 total publications; 3) new renovated laboratory space; 4) numerous presentations; 5) establishing new collaborations; and 6) >$75 million in total new grant funding by H&T members. This Phase II proposal builds on our Phase I success, extends and strengthens the scope of the program, and provides a roadmap for sustainability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inflammation Resolving Lipid Mediators: Novel Therapy for Alcohol AssociatedLiver Disease
Alcoholic Hepatitis Network 3/9 University of Louisville
  • 批准号:
    9752421
  • 项目类别:
  • 资助金额:
    $37.37万
  • 财政年份:
    2018
  • 负责人:
    CRAIG J. MCCLAIN
  • 依托单位:
Alcoholic Hepatitis Network 3/9 University of Louisville
  • 批准号:
    10434741
  • 项目类别:
  • 资助金额:
    $34.96万
  • 财政年份:
    2018
  • 负责人:
    CRAIG J. MCCLAIN
  • 依托单位:
Alcoholic Hepatitis Network 3/9 University of Louisville
  • 批准号:
    10202391
  • 项目类别:
  • 资助金额:
    $36.33万
  • 财政年份:
    2018
  • 负责人:
    CRAIG J. MCCLAIN
  • 依托单位:
海外基金